氟马替尼基础与临床研究进展  

Advances in basic and clinical research of flumatinib

作　　者：江磊 杨明珍[1] Jiang Lei;Yang Mingzhen(Department of Hematology,the First Affiliated Hospital of Anhui Medical University,Anhui Public Health Clinical Center,Hefei 230032,China)

机构地区：[1]安徽医科大学第一附属医院血液内科,安徽省公共卫生临床中心,合肥230032

出　　处：《中华血液学杂志》2024年第6期621-624,共4页Chinese Journal of Hematology

基　　金：安徽省高校自然科学研究项目(KJ2017A833);安徽省卫生健康委员会科研项目(AHWJ2021b077);安徽省第一届卫生健康“骨干人才”项目。

摘　　要：慢性髓性白血病(CML)是一种起源于多能造血干细胞的恶性血液病。伊马替尼是第一代小分子酪氨酸激酶抑制剂(TKI),使CML的治疗取得了革命性进展。氟马替尼为我国自主研发的新型口服TKI药物,可作为CML治疗的优选方案。基础研究提示氟马替尼对CML细胞株抑制作用强于伊马替尼,临床试验及真实世界中氟马替尼对CML疗效均优于伊马替尼,且氟马替尼对Ph染色体阳性急性淋巴细胞白血病、ABL特定突变CML及部分实体瘤有疗效。不良反应可控,安全可耐受。Chronic myelogenous leukemia(CML)is a hematological malignancy originating from the pluripotent hematopoietic stem cells.Imatinib is the first generation of small molecule tyrosine kinase inhibitors(TKI)that revolutionized the treatment of CML.Flumatinib,as a novel oral TKI that independently developed in China,which can be used as a preferred treatment for CML.Basic researches suggested that the inhibitory effect of flumatinib on CML cell lines is stronger than imatinib.Flumatinib demonstrated that it has better efficacy than imatinib on CML in clinical trials and in real world studies.Flumatinib also showed a higher potency against CML with specific mutations,Ph+acute lymphoblastic leukemia and some solid tumors.The adverse events are manageable and tolerable.

关 键 词：伊马替尼 多能造血干细胞 慢性髓性白血病 急性淋巴细胞白血病 临床试验 恶性血液病 基础与临床研究 实体瘤 

分 类 号：R979.1[医药卫生—药品]